Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with Doxorubicin for Recurrent Retroperitoneal Sarcoma
NCT03792867Unknown
- Sponsor
- National Cancer Centre Singapore
- Start
- Jul 2018
- Primary completion
- Feb 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label trial of doxorubicin in retroperitoneal sarcoma (RPS), sponsored by National Cancer Centre Singapore. Primary endpoint: Adverse Events at 1 year. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
retroperitoneal sarcoma (RPS)
Beyond the preview
Go deeper on NCT03792867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792867.